Etanercept is a Fusion Protein owned by Amgen, and is involved in 92 clinical trials, of which 87 were completed, and 5 are ongoing.

Etanercept is a human tumor necrosis factor receptor p75 fc fusion protein produced by recombinant DNA technology in a chinese hamster ovary (CHO) mammalian cell expressing system. Etanercept inhibits binding of both TNF alpha and TNF beta (lymphotoxin alpha [LT aplha]) to cell surface TNFRs, rendering TNF biologically inactive.

The revenue for Etanercept is expected to reach a total of $34bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Etanercept NPV Report.

Etanercept is currently owned by Amgen. Pfizer is the other company associated in development or marketing of Etanercept.

Etanercept Overview

Etanercept (Enbrel, Enbrel PFS) is a dimeric fusion protein, immunomodulator and an antirheumatic agent. It is formulated as solution and powder for solution for subcutaneous route of administration. It is indicated for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older and active ankylosing spondylitis (AS). It is also indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate(MTX) in the treatment of psoriatic arthritis. In addition, it is also used for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy and plaque psoriasis in pediatric patients. Enbrel for pediatric use injection is only used for juvenile idiopathic arthritis and pediatric plaque psoriasis. Enbrel is indicated for the treatment of patients 4 to 17 years with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. It is also indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Enbrel has not been studied in children less than 2 years of age. It is indicated for the treatment of non-radiographic axial spondyloarthritis.

The drug candidate is under development as a monotherapy for psoriatic arthritis and in maintaining remission of rheumatoid arthritis. It was also under development for the treatment of Wegener's granulomatosis and hidradenitis suppurativa.

It was under development for the treatment of palmoplantar pustulosis.

Amgen Overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

The company reported revenues of (US Dollars) US$25,979 million for the fiscal year ended December 2021 (FY2021), an increase of 2.2% over FY2020. In FY2021, the company’s operating margin was 29.4%, compared to an operating margin of 35.9% in FY2020. In FY2021, the company recorded a net margin of 22.7%, compared to a net margin of 28.6% in FY2020. The company reported revenues of US$6,652 million for the third quarter ended September 2022, an increase of 0.9% over the previous quarter.

Quick View – Etanercept

Report Segments
  • Innovator (NME)
Drug Name
  • Etanercept
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Immunology
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.